49th week of 2014 patent applcation highlights part 44 |
Patent application number | Title | Published |
20140356325 | NOVEL 2'-C-METHYL NUCLEOSIDE DERIVATIVE COMPOUNDS - Compositions and methods relating to 2′-C-methyl nucleoside 5′-monophosphate derivative compounds are provided. In some embodiments, the novel compounds are useful to treat viral infections. In particular, 2′-C-methyl nucleoside 5′-monophosphate derivative compounds, stereoisomers, and pharmaceutically acceptable salts or prodrugs thereof, their preparation, and their uses for the treatment of viral infection are described. | 2014-12-04 |
20140356326 | BIOLOGICALLY ACTIVE PROTEINS HAVING INCREASED IN VIVO AND/OR IN VITRO STABILITY - The present invention provides unstructured recombinant polymers (URPs) and proteins containing one or more of the URPs. The present invention also provides microproteins, toxins and other related proteinaceous entities, as well as genetic packages displaying these entities. The present invention also provides recombinant polypeptides including vectors encoding the subject proteinaceous entities, as well as host cells comprising the vectors. The subject compositions have a variety of utilities including a range of pharmaceutical applications. | 2014-12-04 |
20140356327 | GENE THERAPY FOR SPINAL CORD DISORDERS - The disclosure pertains to methods and compositions for treating disorders affecting the central nervous system (CNS). These disorders include neurometabolic disorders such as lysosomal storage diseases that affect the central nervous system, e.g., Niemann-Pick A disease. They also include disorders such as Alzheimer's disease. The disclosed methods involve contacting an axonal ending of a neuron with a composition containing high titer AAV carrying a therapeutic transgene so that the AAV vector is axonally transported in a retrograde fashion and transgene product is expressed distally to the administration site. | 2014-12-04 |
20140356328 | SUBFAMILY E SIMIAN ADENOVIRUSES A1321, A1325, A1295, A1309, A1316 AND A1322 AND USES THEREOF - Recombinant vectors comprise simian adenovirus A1321 (SAdV-A1321), SAdV-A1325, SAdV-A1295, SAdV-A1309, SAdV-A1316, and/or SAdV-A1322 sequences and a heterologous gene under the control of regulatory sequences. A cell line which expresses simian adenovirus SAdV-A1321, SAdV-A1325, SAdV-A1295, SAdV-A1309, SAdV-A1316, and/or SAdV-A1322 gene(s) is also disclosed. Methods of using the vectors and cell lines are provided. | 2014-12-04 |
20140356329 | PROBIOTICS FOR USE IN REDUCING THE INCIDENCE AND DURATION OF ILLNESS - The present invention provides probiotic compositions suitable for reducing the incidence and duration of human illness. In particular, the present invention provides methods and compositions suitable for preventing disease in young children. In some particularly preferred embodiments, the present invention finds use in the prevention respiratory disease in children. | 2014-12-04 |
20140356330 | NOVEL ISOLATED BACTERIOPHAGE HAVING E. COLI-SPECIFIC BACTERICIDAL ACTIVITY AND ANTIBACTERIAL COMPOSITION COMPRISING THE SAME - The present invention relates to a novel bacteriophage having an | 2014-12-04 |
20140356331 | INJECTABLE CNS-DERIVED ECM FOR TISSUE RECONSTRUCTION - Methods useful for preparing central nervous system (CNS) derived extracellular matrix (ECM) materials, including powders and gels are provided. Also provided are CNS ECM preparations prepared according to those methods, and methods of treating a patient or mammal with CNS injury. | 2014-12-04 |
20140356332 | ENHANCING VESSEL LESION HOMING AND REPAIR POTENTIAL OF STEM CELLS - Disclosed herein are methods of enhancing repair of vascular lesions involving the administration of cells in which TGF-β expression and/or activity has been transiently blocked. Other methods involve the administration of a TGF-β blocking agent to a subject who has a vascular lesion or is at risk of developing a vascular lesion. Alternatively, a TGF-β blocking agent and treated cells are co-administered to a subject in need thereof. | 2014-12-04 |
20140356333 | NAIL STEM CELLS AND METHODS OF USE THEREOF - The present invention is directed to an in vitro method for promoting proliferation, survival, and/or differentiation of K14+, K17+ nail stem cells (NSCs). The instant methods may be used to generate an expanded population of K14+, K17+ NSCs in vitro and expanded NSC populations in which a Wnt pathway is activated are envisioned as therapeutic agents. Methods for screening to identify agents capable of modulating K14+, K17+ NSC proliferation, survival, and/or differentiation are also encompassed herein, as are isolated, pure populations of homogeneous K14+, K17+ NSCs. | 2014-12-04 |
20140356334 | METHODS FOR IMPROVED WOUND CLOSURE EMPLOYING OLIVAMINE AND ENDOTHELIAL CELLS - The present disclosure relates to compositions for and methods of improving wound healing, including compositions for and methods of treating chronic wounds, and compositions for the inhibition and treatment of necrosis and extended quiescence that result in cellular necrosis instead of normal proliferation. The methods for wound healing administer one or more compositions including hydroxytyrosol and oleuropein with cells derived from umbilical cord blood. | 2014-12-04 |
20140356335 | MAMMALIAN FETAL PULMONARY CELLS AND THERAPEUTIC USE OF SAME - A pharmaceutical composition comprising as an active ingredient an isolated population of cell suspension from a mammalian fetal pulmonary tissue is disclosed. The fetal pulmonary tissue is at a developmental stage corresponding to that of a human pulmonary organ/tissue at a gestational stage selected from a range of about 20 to about 22 weeks of gestation. Methods of using the pharmaceutical composition are also disclosed. | 2014-12-04 |
20140356336 | METHOD FOR INDUCING DIFFERENTIATION ENABLING TUMORIGENESIS OF IPS CELLS TO BE SUPPRESSED - The object of the invention is to provide a technique of suppressing tumorigenesis in IPS cells and inducing differentiation into target differentiated cells. In use of a statin and a differentiation inducer, iPS cells are differentiated into target differentiated cells, whereby iPS cells can be differentiated into differentiated cells in which tumorigenesis is suppressed. | 2014-12-04 |
20140356337 | COMPOSITION COMPRISING AN ACTIVATED MICROBIAL BIOMASS - The present invention relates to a composition comprising a substrate capable of being evenly coated with a microbial biomass, wherein said biomass represents from 10% to 30% by dry matter of the total dry matter of the coated substrate. It also relates to a method for preparing said composition and to a starter fermentation activator and to a probiotic comprising said composition. | 2014-12-04 |
20140356338 | RICE-FERMENTED FOOD COMPOSITION CONTAINING RICE SACCHARIFIED LIQUID FERMENTED WITH KIMCHI LACTIC ACID BACTERIA AS ACTIVE INGREDIENT AND HAVING ANTIBACTERIAL AND ANTIVIRAL EFFECTS - Disclosed are a rice-fermented food composition which contains a rice saccharified liquid fermented with kimchi lactic acid bacteria as an active ingredient and has antibacterial and antiviral effects. More particularly, the present invention relates to a rice lactic acid bacteria fermented food composition which is prepared by adding kimchi lactic acid bacteria to a rice saccharified liquid as a main ingredient and fermenting the mixture, and has antibacterial and antiviral effects against atopic dermatitis and avian influenza virus, and a functional health food comprising the same. | 2014-12-04 |
20140356339 | SEQUENCE-BASED MEASURES OF IMMUNE RESPONSE - The invention is directed to methods of measuring an immune response by comparing sequence-based clonotype frequency data from successively measured clonotype profiles. In particular, the invention includes immunotherapies of cancers, such as lymphomas, that include sensitive pre- and post-vaccination sequence-based measurements of changes in a patient's immune repertoire, thereby providing a sensitive measure of the likelihood of treatment success. | 2014-12-04 |
20140356340 | EXTENSIONAL VISCOSITY TO PROMOTE SAFE SWALLOWING OF FOOD BOLUSES - Nutritional products having improved cohesiveness of food boluses and methods of making and using same are provided. The nutritional products may include nutritional compositions and high molecular weight, water-soluble polymers such that the nutritional products have extensional viscosities that provide improved cohesiveness to the nutritional products and Trouton ratios of at least 6. Methods of administering such nutritional products to patients having impaired swallowing ability and/or dysphagia are also provided. | 2014-12-04 |
20140356341 | Medication and treatment for disease - A treatment is described for diseases with symptoms that can include fatigue, muscle aches and spasms, weakness, demylenation, and nerve pain. Diseases can include fibromyalgia, depression, and auto-immune and immuno-suppressive diseases, such as MS. The treatment comprises about 1-10 mg naltrexone, at least about 20 μg vitamin B12, at least about 5 mg vitamin B6, at least about 2 mg coenzyme Q, and preferably at least one ancillary medication selected from the group consisting of diazepam, cyclcobenzaprine, clonazepam, alprazolam, 9-tetrahydrocannibinol, fumarate, caffeine, and combinations thereof. The treatment can be administered orally, and can decrease mental and physical symptoms such as, for example, fatigue, gait problems, visual dysfunction, and pain while improving cognitive skills. | 2014-12-04 |
20140356342 | HUMAN BETA-ADRENERGIC RECEPTOR KINASE POLYPEPTIDE AND METHODS - Various embodiments of the invention provide human kinases and phosphatases (KPP) polypeptides and polynucleotides which identify and encode KPP. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of KPP. | 2014-12-04 |
20140356343 | COMPOSITION FOR TREATING PARKINSON'S DISEASE - A composition useful for the treatment of degenerative brain disease. A pharmaceutical composition comprising an effective amount of apamin as an active ingredient and an effective amount of at least another compound including a permeability enhancer and/or carrier molecule. | 2014-12-04 |
20140356344 | MIRAC PROTEINS - This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures. | 2014-12-04 |
20140356345 | New Proteases Able to Hydrolyze Gluten Peptides and Proteins at Acidic PH, from the Actinomycete Actinoallomurus - The invention relates to a new family of proteolytic enzymes having the ability to hydrolize at a p H between 3 and 8 gluten olygopeptides which are resistant to cleavage by gastric and pancreatic enzymes and whose presence in the intestinal lumen results in toxic effects. The enzymes have been identified as endopeptidases of the S8/S53 family and are produced by an | 2014-12-04 |
20140356346 | MODIFIED COAGULATION FACTOR VIIa WITH EXTENDED HALF-LIFE - The present invention relates to the fields of Factor VII (FVII) and Factor VIIa (FVIIa) albumin linked polypeptides. More specifically, the invention relates to cDNA sequences coding for human Factor VII and Factor VIIa and derivatives genetically fused to a cDNA coding for human serum albumin which may be linked by oligonucleotides which code for intervening peptidic linkers such encoded derivatives exhibiting improved stability and extended functional plasma half-life, recombinant expression vectors containing such cDNA sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives which do have biological activities of the unmodified wild type protein but having improved stability and prolonged shelf-life and processes for the manufacture of such recombinant proteins and their derivatives. The invention also covers a transfer vector for use in human gene therapy, which comprises such modified DNA sequences. | 2014-12-04 |
20140356347 | NOVEL SERINE PROTEASE VARIANTS - The present disclosure provides novel variants of enzymes exhibiting serine protease activity; nucleic acid molecules encoding said proteases, vectors, host cells containing the nucleic acids and methods for preparation and producing such enzymes; compositions and complexes comprising at least one of the proteases; and methods for using such enzymes as a part of an immunoprotease, in particular for the treatment of cancer. | 2014-12-04 |
20140356348 | METHODS OF PREDICTING AND DECREASING THE RISK OF PREGNANCY LOSS - Described are methods for diagnosing and predicting the risk of pregnancy loss in a subject based on the presence of an aberrant humoral response to three proteins, Apolipoprotein B-100, alpha2macrogloblin (alpha2M), and fibronectin. The presence or a detectable level of maternal IgG antibodies to trophoblast-derived fibronectin and/or ApoB-100, and/or the absence or a non-detectable level of antibodies specifically binding to alpha2M is associated with a history of RPL and an increased risk of pregnancy loss. Also described are methods for identifying subjects at risk of pregnancy loss, selecting subjects for participation in a clinical study, and methods of decreasing the risk of pregnancy loss in a subject which include detecting the presence or absence of antibodies to one or more of trophoblast-derived ApoB-100, alpha2M, and fibronectin. Also provided are kits that contain ApoB-100, alpha2M, and fibronectin. | 2014-12-04 |
20140356349 | BIOMARKERS OF RESISTANCE TO HER2 INHIBITORS - Provided is a method of suppressing resistance to an anticancer drug, comprising administering an inhibitor of expression or activity of ECM 1 (Extracellular Matrix Protein 1) to a cancer cell or an individual with cancer. | 2014-12-04 |
20140356350 | COMBINATION THERAPY TO PREVENT DCIS FORMATION AND PROGRESSION TO BREAST CANCER - A method of treating a ductal carcinoma in situ (DCIS) lesion in a subject in need thereof is disclosed. The method comprises administering to the subject a therapeutically effective amount of a first agent capable of down-regulating activity and/or expression of at least one component participating in a NOTCH pathway, and a second agent capable of down-regulating an activity and/or expression of HER2, thereby treating the DCIS lesion. | 2014-12-04 |
20140356351 | METHODS OF TREATING PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS - The present disclosure relates to methods of treating individuals suffering from progressive forms of multiple sclerosis. | 2014-12-04 |
20140356352 | COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A CD79b ANTIBODY-DRUG CONJUGATE - The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with a CD79b antibody-drug conjugate for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and a CD79b antibody-drug conjugate. | 2014-12-04 |
20140356353 | TARGETED BINDING AGENTS AGAINST B7-H1 - Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed. | 2014-12-04 |
20140356354 | THERAPY FOR FILOVIRUS INFECTION - The present invention addresses a need for improved treatments for filovirus infections. | 2014-12-04 |
20140356355 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS - The present invention relates to IL-17 Receptor A (IL-17RA or IL-17R) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation by one or more IL-17 ligands. The present invention relates to the identification of neutralizing determinants on IL-17 Receptor A (IL-17RA or IL-17R) and antibodies that bind thereto. Aspects of the invention also include antibodies that compete for binding with the IL-17RA neutralizing antibodies described herein. | 2014-12-04 |
20140356356 | Use of IL-1 beta Binding Antibodies - The present invention relates to an IL-1β binding antibody or a functional fragment thereof for use in preventing or reducing risk of experiencing a recurrent cardiovascular (CV) event or a cerebrovascular event in a patient that has suffered of a qualifying CV event. | 2014-12-04 |
20140356357 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY DISEASES - A monoclonal secretory IgA antibody, which binds to and neutralizes human TNFα. The secretory antibody is useful in treating a variety of inflammatory conditions in humans. | 2014-12-04 |
20140356358 | VARIANT FC-POLYPEPTIDES WITH ENHANCED BINDING TO THE NEONATAL FC RECEPTOR - Described herein are variant Fc-fragments that contain an insertion within or adjacent to a loop that bind to the neonatal Fc receptor (FcRn) with higher affinity and/or higher binding activity at pH 5-6 and approximately the same or lower affinity at a physiologic pH as compared to a control Fc-fragment, that is, little or no binding activity at a physiologic pH. Also described are variant Fc-polypeptides that comprise these variant Fc-fragments. Further described are methods of making and identifying such Fc-fragments and methods for making and using such Fc-polypeptides. | 2014-12-04 |
20140356359 | HUMAN GROWTH HORMONE RECEPTOR ANTAGONIST ANTIBODIES AND METHODS OF USE THEREOF - The present invention provides antagonizing antibodies that bind to growth hormone receptor (GHR). The invention further relates to therapeutic methods for use of these antibodies to reduce IGF-1 levels and/or for the treatment and/or prevention of diseases associated with excessive IGF-1, including treatment of acromegaly, gigantism, cancer, diabetic nephropathy, arthritis, and lung inflammation. | 2014-12-04 |
20140356360 | PIPERAZINYL DERIVATIVES FOR THE TREATMENT OF CANCER - The present invention relates to piperazinyl derivatives of formula (I) and the use thereof as a drug, particularly for the treatment of cancer, the pharmaceutical compositions containing said derivatives, and the method for synthesising same. | 2014-12-04 |
20140356361 | REPEATED ADMINISTRATION OF NON-IMMUNOSUPPRESSIVE ANTIGEN SPECIFIC IMMUNOTHERAPEUTICS - This invention relates to repeated administration of antigen-specific immunotherapeutics using protocols, or elements thereof, that do not induce immunosuppression. In some embodiments, the protocol has been previously shown not to induce immunosuppression in a subject. | 2014-12-04 |
20140356362 | TARGETED/IMMUNOMODULATORY FUSION PROTEINS AND METHODS FOR MAKING SAME - The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells. | 2014-12-04 |
20140356363 | Antigen Binding Proteins that Bind PD-1 - There is disclosed compositions and methods relating to or derived from anti-PD-1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-1, PD-1-binding fragments and derivatives of such antibodies, and PD-1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-1 related disorders or conditions, including various inflammatory disorders and various cancers. | 2014-12-04 |
20140356364 | Anti-B7-H4 Antibodies and Their Uses - The present invention relates to antibodies (including anti-B7-H4 antibodies) and their antigen-binding fragments and to other molecules (including fusion proteins that bind to the cognate antigen/receptor, etc.) that are capable of immunospecifically binding to B7-H4 and the uses of such molecules in the diagnosis and the treatment of cancer and other diseases. The invention particularly concerns the use of such molecules to retard or prevent tumor growth, inhibit tumor-mediated suppression, eliminate tumors and/or deplete or block the activity of tumor associated macrophages (“TAMs”) so as to alter their activity and/or decrease TAM—mediated immune suppression. | 2014-12-04 |
20140356365 | PROGNOSTIC, SCREENING AND TREATMENT METHODS AND AGENTS FOR TREATMENT OF METSTASIS AND INFLAMMATION USING T54 ONCOFOETAL GLYCOPROTEIN - Methods and agents are disclosed based on the finding that 5T4 interacts with CXCR4 in the cell membrane to form a complex, and that the 5T4 transmembrane region is involved in the promotion of CXCR4 membrane expression and chemotactic response. | 2014-12-04 |
20140356366 | COMPOSITION FOR TARGET MEMBRANE PROTEIN DEPLETION - A method of target membrane protein depletion comprising treating a cell with a dual binding molecule comprising a first binding domain which binds to a driver membrane protein and a second binding domain which binds to a target membrane protein, wherein the cell comprises a cell membrane, and the driver membrane protein and target membrane protein are associated with the cell membrane where the target membrane protein positions, and are internalized into a cell and degraded when the first binding domain of the dual binding molecule binds the driver membrane protein; as well as related methods and compositions. | 2014-12-04 |
20140356367 | MONOPHOSPHORYLATED LIPID A DERIVATIVES - The present invention provides for monophosphorylated lipid A derivatives and carbohydrate derivatives that are useful as agents in the treatment of diseases and conditions, including cancers. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I-IV. In addition, methods for the treatment of cancers are provided. | 2014-12-04 |
20140356368 | APPLICATIONS OF AN IMMUNE SYSTEM-RELEASED ACTIVATING AGENT (ISRAA) - The present invention relates to applications of an immune system-released activating agent (ISRAA) polypeptide, which is induced by a nervous stimulus and which has been found to mediate the transmission of signals between the immune system and the nervous system following an immune challenge. Here, the ISRAA polypeptide is for use in a method of treatment of patients with immunodeficiency, immunosuppression or autoimmune disease; cancer; neurologic diseases and disorders; or muscular diseases and disorders. | 2014-12-04 |
20140356369 | ANTIBODIES TO HUMAN GDF8 - The present invention provides isolated human or humanized antibodies or antigen-binding fragments thereof which specifically bind to Growth and Differentiation Factor-8 (GDF8) and block GDF8 activity. The antibodies and antibody fragments of the present invention may be used in therapeutic methods for treating conditions or disorders which are ameliorated or improved by inhibition of GDF8. | 2014-12-04 |
20140356370 | METHODS FOR TREATING AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA ASSOCIATED WITH PCSK9 GAIN-OF-FUNCTION MUTATIONS - The present invention provides methods for treating autosomal dominant hypercholesterolemia (ADH). According to certain embodiments, the ADH is caused by or associated with a gain-of-function mutation (GOFm) in a gene encoding PCSK9. The present invention therefore includes methods comprising selecting a patient who carries a GOFm in one or both alleles of the PCSK9 gene, and administering to the patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P. | 2014-12-04 |
20140356371 | METHODS FOR REDUCING REMNANT CHOLESTEROL AND OTHER LIPOPROTEIN FRACTIONS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9) - The present invention provides methods for reducing various lipoprotein fractions in the serum of patients. The methods of the invention include reducing serum remnant cholesterol, and/or the serum concentration of one or more LDL-C subfractions in a patient. The methods of the present invention comprise selecting a patient who exhibits elevated serum lipoproteins, and administering to the patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P. | 2014-12-04 |
20140356372 | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R inhibitor - The present invention provides methods for treating, preventing or reducing the severity of allergic reactions. The present invention also provides methods for enhancing the efficacy and/or safety of an allergen-specific immunotherapy (SIT) regimen. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4Rα) antagonist such as an anti-IL-4Rα antibody. | 2014-12-04 |
20140356373 | METHODS AND COMPOSITIONS FOR TREATING LUPUS - The invention relates to compositions and methods for treating lupus. The methods typically comprise the step of administrating one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA in an amount sufficient to treat the lupus; preferably by modulating cytokine expression. Preferably the compound is in an amount less than sufficient to substantially inhibit cyclin dependent kinases. | 2014-12-04 |
20140356374 | METHODS FOR TREATMENT OF MUSCULAR DYSTROPHY - The present invention relates to methods and agents useful for treating muscular dystrophy. Methods and agents for treating various physiological and pathological features associated with muscular dystrophy are also provided. | 2014-12-04 |
20140356375 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES - The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same. | 2014-12-04 |
20140356376 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES - The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same. | 2014-12-04 |
20140356377 | COMPOUNDS FOR USE IN BOOSTING COAGULATION - The present invention relates to inhibitors of antithrombin III and the medical use thereof in treating or preventing bleeding. The inhibitors are preferably used in subjects suffering from an acquired or genetic bleeding disorder, such as haemophilia, or in a subjects having a clinical condition characterised by excessive bleeding, such as surgery, trauma and internal bleeding. The inhibitor of antithrombin III can e.g. a peptide, an aptamer or an antibody or antibody fragment that specifically binds to and inhibits antithrombin III. | 2014-12-04 |
20140356378 | BMP-1 Procollagen C-Proteinase for Diagnosis and Treatment of Bone and Soft Tissue Defects and Disorders - Uses of BMP-1 isoforms for diagnosing and treating defects and disorders of bone and soft tissues are described. Also described is a newly isolated variant of the BMP-1 isoform BMP-1-3. | 2014-12-04 |
20140356379 | ANTI-SPLA2-V ANTIBODIES AND USES THEREOF - The present disclosure relates to isolated antibodies against human SPLA2-V and uses thereof. | 2014-12-04 |
20140356380 | Neutralizing Antibodies And Methods Of Use Thereof - This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using the monoclonal antibodies as therapeutics. This invention also provides soluble chimeric proteins, methods of expressing and purifying soluble chimeric proteins, and methods of using soluble chimeric proteins as therapeutics, in screening assays and in the production of antibodies. | 2014-12-04 |
20140356381 | METHODS OF PURIFYING HETERODIMERIC PROTEINS USING IMMUNOGLOBULIN CLASS SWITCHING - The present invention describes novel immunoglobulin compositions that co-engage at least two antigens, e.g. a first and second antigen, or, as outlined herein, three or four antigens can be bound, in some of the scaffold formats described herein. First and second antigens of the invention are herein referred to as antigen-1 and antigen-2 respectively (or antigen-3 and antigen-4, if applicable. As outlined herein, a number of different formats can be used, with some scaffolds relying combinations of monovalent and bivalent bindings. | 2014-12-04 |
20140356382 | Exosomes for Delivery of Biotherapeutics - The present invention relates to exosomes, loaded with biotherapeutic protein and/or peptide and methods of producing them and to the use of such exosomes for delivering protein and/or peptide in vivo, in particular the use of such exosomes in methods of therapy. | 2014-12-04 |
20140356383 | ADMINISTRATION OF AN ANTI-GCC ANTIBODY-DRUG CONJUGATE AND A DNA DAMAGING AGENT IN THE TREATMENT OF CANCER - The present invention relates to methods for the treatment of gastrointestinal cancers. In particular, the invention provides methods for treatment of a gastrointestinal cancer by administering an immunoconjugate comprising an anti-GCC antibody molecule in combination with a DNA damaging agent. | 2014-12-04 |
20140356384 | ERYTHROCYTE-BINDING THERAPEUTICS - Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired. | 2014-12-04 |
20140356385 | ENZYMATIC CONJUGATION OF ANTIBODIES - The present application relates to methods for the functionalization of immunoglobulins, in particular with drugs. Also disclosed herein are linking reagents, functionalized antibodies, pharmaceutical compositions, and method of treating disease and/or conditions. | 2014-12-04 |
20140356386 | IMMUNIZATION PROTOCOL FOR DIRECTED EXPANSION AND MATURATION - A first antigen is administered to a subject to select progenitor B cells that are suitable for subsequent production of a desirable affinity-matured antibody, and then a second antigen is administered to stimulate the expansion of B cells that produce that affinity-matured antibody. An immunization protocol is used in which two different antigens are administered (usually in series, but in some embodiment simultaneously), where the first antigen elicits an efficient germline antibody response and the second antigen elicits an efficient and desired affinity-matured antibody response. | 2014-12-04 |
20140356387 | METHOD FOR INDUCING IMMUNE TOLERANCE THROUGH TARGETTED GENE EXPRESSION - A method of inducing immune tolerance against a protein of interest comprising the steps of (a) transducing hematopoietic stem cells with a gene for the protein of interest wherein the gene is operably connected to a platelet specific promoter, and (b) transplanting the transfected cells of step (a) into to a subject, wherein the protein is expressed, and wherein the subject develops immune tolerance against the protein. | 2014-12-04 |
20140356388 | Vaccine - Screening Method - The present invention provides screening methods which may be regarded as in vitro or ex vivo methods of interrogating the immune system to understand what viral antigens are “seen” and responded to by T cells of the immune systems during viral infection. The screening methods further link in vitro or ex vivo responses to progression of infection in subjects. | 2014-12-04 |
20140356389 | PROTEINS AND NUCLEIC ACIDS FROM MENINGITIS/SEPSIS-ASSOCIATED ESCHERICHIA COLI - Disclosed herein are various open reading frames from a strain of | 2014-12-04 |
20140356390 | MODULATION OF REPLICATIVE FITNESS BY DEOPTIMIZATION OF SYNONYMOUS CODONS - Methods of producing a pathogen with reduced replicative fitness are disclosed, as are attenuated pathogens produced using the methods. In particular examples, the method includes deoptimizing one or more codons in a coding sequence, thereby reducing the replicative fitness of the pathogen. Methods of using the attenuated pathogens as immunogenic compositions are also disclosed. | 2014-12-04 |
20140356391 | AMINO ACID SEQUENCES FOR CLINICAL REMISSION OF PSORIASIS AND RELATED DISEASES. - Polypeptides comprising amino acid sequences of particulate antigens isolated from various species of | 2014-12-04 |
20140356392 | MODULATORS OF MYC, METHODS OF USING THE SAME, AND METHODS OF IDENTIFYING AGENTS THAT MODULATE MYC - Disclosed herein are methods of modulation of the viability of a cell. Further disclosed herein are methods of modulating an immune response. Further disclosed herein are methods of identifying agents capable of modulation of the viability of a cell or an immune response. Further disclosed herein are agents and compositions capable of modulation of the viability of a cell or an immune response. | 2014-12-04 |
20140356393 | COMPOSITION FOR TREATMENT OR PREVENTION OF HYPERLIPIDEMIA, CONTAINING WATER EXTRACTS OF LAETIPORUS SULPHUREUS - The present invention relates to a composition for the treatment or prevention of hyperlipidemia, the composition containing water extracts of | 2014-12-04 |
20140356394 | COMPOSITION FOR TREATMENT OR PREVENTION OF OBESITY, CONTAINING WATER EXTRACTS OF FOMITELLA FRAXINEA - The present invention relates to a composition for the treatment or prevention of obesity, the composition containing water extracts of | 2014-12-04 |
20140356395 | METHODS AND MATERIALS FOR PRODUCING IMMUNE RESPONSES AGAINST POLYPEPTIDES INVOLVED IN ANTIBIOTIC RESISTANCE - This document relates to methods and materials for producing immune responses against polypeptides involved in antibiotic resistance. For example, vaccines against polypeptides involved in antibiotic resistance as well as methods for vaccinating mammals against polypeptides involved in antibiotic resistance are provided. | 2014-12-04 |
20140356396 | ROTAVIRUS PREPARATIONS WITH EXCESS CALCIUM IONS AND HIGH VISCOSITIES THAT ENSURE VIABILITY AT ELEVATED TEMPERATURES - The invention describes a set of formulations and methods that provide for stabilization of viruses in liquid and dried states. In particular, formulations include Rotavirus preparations with excess Ca2+ and high viscosities that ensure infective potency at elevated temperatures. Methods include bulk purification of Rotavirus from cell culture and administration of formulations as vaccines including components for gastric neutralization. | 2014-12-04 |
20140356397 | Immunogenic Treatment Of Cancer - The present invention provides an immunomodulator for use in the treatment and/or control of a neoplastic disease in a patient intended to undergo immunogenic cell death therapy simultaneously, separately or sequentially with administration of the immunomodulator. The therapy can be selected from microwave irradiation, targeted radiotherapy, embolization, cryotherapy, ultrasound, high intensity focused ultrasound, cyberknife, hyperthermia, radiofrequency ablation, cryoablation, electrotome heating, hot water injection, alcohol injection, embolization, radiation exposure, photodynamic therapy, laser beam irradiation, and combinations thereof. | 2014-12-04 |
20140356398 | ADOPTIVE TRANSFER OF CD8+ T CELL CLONES DERIVED FROM CENTRAL MEMORY CELLS - The present invention provides a method of carrying out adoptive immunotherapy in a primate subject in need thereof by administering the subject a cytotoxic T lymphocytes (CTL) preparation in a treatment-effective amount. The method comprises administering as the CTL preparation a preparation consisting essentially of an in vitro expanded primate CTL population, the CTL population enriched prior to expansion for central memory T lymphocytes, and depleted prior to expansion of effector memory T lymphocytes. In some embodiments, the method may further comprise concurrently administering Interleukin-15 to the subject in an amount effective to increase the proliferation of the central memory T cells in the subject. Pharmaceutical formulations produced by the method, and methods of using the same, are also described. | 2014-12-04 |
20140356399 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS - The present disclosure provides compositions and methods useful for treating viral infections. As described herein, the compositions and methods are based on the development of immunogenic compositions that include an inactivated virus in combination with a non-ionic surfactant vesicle (NISV). In certain embodiments at least a portion of the antigen present in the composition is physically associated with the NISV. In certain embodiments the compositions are lyophilized and subsequently rehydrated after a period of storage. In certain embodiments the rehydrated compositions exhibit greater potency as compared to otherwise equivalent compositions that lack the NISV. In certain embodiments the lyophilized compositions are stored at temperatures in excess of 8° C. prior to rehydration. In certain embodiments the rehydrated compositions exhibit greater potency as compared to otherwise equivalent compositions that lack the NISV and that were also stored at temperatures in excess of 8° C. prior to rehydration. In certain embodiments the antigen is taken from a licensed vaccine and the administered dose of antigen is less than the standard human dose for the licensed vaccine. | 2014-12-04 |
20140356400 | SIMPLE MICRO-PARTICULATE SUSPENSION OF BEHENTRIMONIUM CHLORIDE WITH FAVORABLE DISTRIBUTIVE AND ADSORPTIVE PROPERTIES - A personal care composition for hair and skin applications includes an aqueous solution consisting essentially of aggregates of behentrimonium chloride and dihydroxypropyl PEG-5 linoleammonium chloride. The composition forms micro particles or aggregates of behentrimonium chloride that exhibits surprising distributive properties in aqueous solution of a nature beneficial to its application to hair or skin surfaces. | 2014-12-04 |
20140356401 | LIQUID COSMETIC - A liquid cosmetic which minimizes stickiness or stiffness caused by the incorporation of a large amount of a moisturizing agent is provided. This liquid cosmetic contains 10 to 40% by mass of a moisturizing agent (a), 0.01 to 3% by mass of an oil (b), 0.01 to 5% by mass of a hydrophilic surfactant (c), and 0.001 to 0.3% by mass polyacrylic acid or a metal salt thereof (d), and wherein an average emulsified particle size is 500nm or smaller. Preferably, the amount of polyalkylene glycol contained in the moisturizing agent (a) is adjusted to 0.1 to 3 mass % relative to the whole cosmetic. | 2014-12-04 |
20140356402 | COLOUR CHANGING COMPOSITION - A changing colour composition for caring for and/or making up keratin materials is disclosed. The composition comprises in a physiologically acceptable medium, at least: a) microcapsules containing releasable colorant(s), said microcapsules comprising: a core comprising one organic material, at least one layered coating surrounding said core, the layered coating comprising at least one polymer, at least one colorant, and advantageously at least one lipid-based material, b) at least 3% by weight, preferably at least 5 by weight, more preferably at least 8% by weight and advantageously at least 10% by weight relative to the weight of the composition of an aqueous phase comprising water and at least one compound chosen from polyols, glycols and C | 2014-12-04 |
20140356403 | COLOUR CHANGING COMPOSITION IN GEL FORM - A changing colour composition in the form of a gel for caring for and/or making up keratin materials is disclosed. The composition comprises in a physiologically acceptable medium, a) from 0.1 to 10% by weight preferably from 0.5 to 10% more preferably from 1 to 5% by weight relative to the weight of the composition of microcapsules containing releasable colorant(s), said microcapsules comprising:—a core comprising one organic material,—at least one layered coating surrounding said core, the layered coating comprising at least one polymer at least one colorant, and advantageously at least one lipid-based material, b) at least 3% by weight, preferably at least 5% by weight, more preferably at least 8% by weight and advantageously at least 10% by weight relative to the weight of the composition of an aqueous phase comprising water and at least one compound chosen from polyols, glycols and C2-C8 monoalcohols, and mixtures thereof, and c) at least one hydrophilic gelifying agent. | 2014-12-04 |
20140356404 | ACTIVE-POWDER BIOCIDAL COMPOSITION COMPRISING AT LEAST ONE COPPER SALT AND AT LEAST ONE ZINC SALT AND THE METHOD FOR THE PRODUCTION THEREOF - Active-powder biocidal composition comprising at least one copper salt and at least one zinc salt such that the molar ratio between the copper salt and the zinc salt is within the range of 10 to 1 and each copper and zinc salt, separately, has a solubility constant (Kps) within the range from a value greater than or equal to 1*10-20 to a value less than or equal to 9*10-6. Also included is the biocidal composition that comprises the active-powder composition and a polymer, and the method for the production of said biocidal composition, which comprises: thoroughly mixing the salts in such a manner as to obtain a homogeneous distribution of an active-powder biocidal composition; controlling the mixing temperature such that it remains at approximately less than 50° C.; and mixing the resulting mixture of active powders with a polymer. | 2014-12-04 |
20140356405 | Antimicrobial Constructs - The invention is based on the recognition that known antimicrobial compounds, such as nisin or other lantibiotics, can be made to form a long lasting antimicrobial surface coating by linking the peptide with a block polymer, such as PLURONIC® F108 or an end group activated polymer (EGAP) in a manner to form a flexible tether and/or entrap the peptide. The entrapped peptide provides antimicrobial action by early release from entrapment while the tethered peptide provides longer lasting antimicrobial protection. Antimicrobial gels and foams may be prepared using the antimicrobial peptide containing block copolymers. | 2014-12-04 |
20140356406 | Antimicrobial Articles and Methods of Making and Using Same - Described herein are glass or glass-ceramic articles having improved antimicrobial efficacy. Further described are methods of making and using the improved articles. The improved articles generally include a glass or glass-ceramic substrate, a compressive stress layer that extends inward from a surface of the glass or glass-ceramic substrate to a first depth therein, and an antimicrobial agent-containing region that extends inward from the surface of the glass or glass-ceramic substrate to a second depth therein. The antimicrobial agent-containing region may include at least one of a plurality of ion exchanged-copper ions and a plurality of ion exchanged-silver ions, arranged in a predetermined portion of the surface. | 2014-12-04 |
20140356407 | BIODEGRADABLE SUPPORTING DEVICE - A biodegradable in vivo supporting device is disclosed. The in vivo supporting device comprises a biodegradable metal scaffold and a biodegradable polymer coating covering at least a portion of the biodegradable metal scaffold, wherein the biodegradable polymer coating has a degradation rate that is faster than the degradation rate of the biodegradable metal scaffold. | 2014-12-04 |
20140356408 | POLYMERIC COMPOSITIONS CONTAINING AMBIENT-TEMPERATURE STABLE BIOPHARMACEUTICALS & METHODS FOR FORMULATION THEREOF - Biopharmaceuticals, such as vaccine agents and probiotics, are encapsulated in carbohydrate-glass particles and embedded in an amorphous polymer substrate to produce polymeric compositions containing ambient-temperature stable biopharmaceuticals for syringeless administration to patients such as via dissolvable films, micro-needle patches and similar medical delivery devices. The amorphous polymer substrate is soluble in both water and volatile organic solvents, yet the carbohydrate-glass particles are insoluble in organic solvents. A method for formulation of the polymeric compositions containing ambient-temperature stable biopharmaceuticals includes combining biopharmaceuticals encapsulated in carbohydrate-glass particles with polymer in organic solvent and evaporating the organic solvent to yield a water soluble polymeric composition containing ambient-temperature stable biopharmaceuticals. | 2014-12-04 |
20140356409 | CATIONIC PEPTIDES AND USE OF SUCH PEPTIDES FOR INHIBITING EXOTOXIN PRODUCTION - Cationic peptides and use of such peptides to inhibit bacterial exotoxin production without substantially inhibiting bacterial growth are described. | 2014-12-04 |
20140356410 | BIODEGRADABLE AND BIOCOMPATIBLE NANO COMPOSITE T-PLATE IMPLANT AND A METHOD OF SYNTHESIZING THE SAME - The embodiments herein provide a biodegradable and biocompatible T-plate nano-composite implant with stem cells for treating and repairing broken bones, damaged tissues and torn ligaments. The implant comprises a polymeric matrix part comprising poly lactic glycolic acids (PLGA), a bioceramic part comprising hydroxyapatite (HAp) nanoparticles and an endometrial stem cell. The PLGA and HAp nanoparticles act as a matrix and reinforcing agents respectively. A method is provided for synthesizing the T-plate implant. The method comprises synthesizing hydroxyapatite (HAp) nanoparticles, poly lactic glycolic acids (PLGA) and HAp nano composite implant. The casting of the poly lactic glycolic acids (PLGA) and HAp nano composite are done in a mold to obtain a T-plate nano composite. An endometrial stem cell from an epithelial cell lining from uterus is isolated and cultured. The endometrial stem cells are implanted on the nano-composite implant. | 2014-12-04 |
20140356411 | PLASMONIC-MAGNETIC BIFUNCTIONAL NANOTUBES FOR BIOLOGICAL APPLICATIONS - The present invention includes nanotubes or rods, methods and arrays using plasmonic-magnetic bifunctional nanotubes or rods comprising: one or more silica nanotubes or rods; one or more nanomagnets embedded in a portion of the silica nanotubes or rods; and plasmonic metal nanoparticles uniformly coating in or on at least a portion of the surface of the nanomagnets and the silica nanotubes surface-coated. | 2014-12-04 |
20140356412 | Non-Aqueous Patch | 2014-12-04 |
20140356413 | RETINOID-LIPOSOMES FOR TREATING FIBROSIS - What is described are pharmaceutical compositions comprising a double-stranded nucleic acid molecule comprising a sense strand and an antisense strand wherein the sense and antisense strands are selected from the oligonucleotides described as SERPINH1_2 (SEQ ID NOS: 60 and 127), SERPINH1_45a (SEQ ID NOS: 98 and 165), and SERPINH1_51 (SEQ ID NOS: 101 and 168), and drug carrier comprising a mixture of a retinoid and a lipid vesicle, and methods of using these pharmaceutical compositions to treat a disease associated with hsp47 espresssion, including fibrosis. | 2014-12-04 |
20140356414 | Targeted Crosslinked Multilamellar Liposomes - A liposome composition that is useful for treating a subject in need of cancer treatment includes a cross-linked multilamellar liposome having an exterior surface and an interior surface. The interior surface defines a central liposomal cavity. The multilamellar liposome includes at least a first lipid bilayer and a second lipid bilayer. The first lipid bilayer is covalently bonded to the second lipid bilayer. At least one anticancer compound is disposed within the multilamellar liposome. Methods for treating subjects are also provided. | 2014-12-04 |
20140356415 | COMPOSITIONS AND VACCINES COMPRISING VESICLES AND METHODS OF USING THE SAME - The disclosure relates to compositions, pharmaceutical compositions, vaccines, and methods of making and using the same. The compositions of the disclosure are useful to stimulate an antigen-specific immune response and, in some embodiments, a protective immune response in an animal after challenge to pathogens. The compositions of the disclosure are also useful for treatment and prevention of disease in a subject such as cancer. | 2014-12-04 |
20140356416 | LIPOSOMAL DRUG ENCAPSULATION - Provided herein are novel methods of making liposomally encapsulated drugs using reverse pH gradients and optimizing internal buffer compositions. Further provided herein are liposome compositions including an active pharmaceutical ingredient and uses thereof to treat a variety of diseases (e.g. cancer, inflammatory, neurological and cardiovascular diseases). | 2014-12-04 |
20140356417 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES - Drag derivatives are provided herein which are suitable for loading into liposomal nanoparticle carriers. In some preferred aspects, the derivatives comprise a poorly water-soluble drag derivatized with a weak-base moiety that facilitates active loading of the drag through a LN transmembrane pH or ion gradient into the aqueous interior of the LN. The weak-base moiety can optionally comprise a lipophilic domain that facilitates active loading of the drag to the inner monolayer of the liposomal membrane. Advantageously, LN formulations of the drag derivatives exhibit improved solubility, reduced toxicity, enhanced efficacy, and/or other benefits relative to the corresponding free drags. | 2014-12-04 |
20140356418 | COMPOSITIONS FOR BINDING TO AMYLOID PROTEINS - Compositions useful for the prevention and/or treatment of Alzheimer's disease are disclosed. The composition comprises carrier particles each linked to a plurality of peptide constructs comprising a peptide binding sequence capable of binding to an amyloid protein and a transit amino acid sequence linked to said binding sequence. The binding sequence may be retroinverted D-peptide mimetic of an L-peptide binding sequence and the transit sequence may be a D-peptide mimetic of an L-peptide transit sequence (e.g. TAT) The preferred peptide construct comprises the sequence rGffvlkGrrrrqrrkkrGy. The preferred carrier particles are liposomes. | 2014-12-04 |
20140356419 | Polyherbal Composition for Skin Care - Described herein is a polyherbal composition effective in skin care, including singularly or in certain combinations 0.01% to 15% of | 2014-12-04 |
20140356420 | MICRO-PARTICLE COMPRISING A PROTEIN EXTRACT FROM SWEET POTATO FOR EXTENDING SATIETY AND CONTROLLING BLOOD GLUCOSE AND LIPID LEVELS - The present invention relates to a micro-particle for extending satiety and controlling blood glucose and lipid levels, comprising a core having the protein extract from sweet potato, an active ingredient layer coated on the core, and a protection layer coated over the active ingredient layer as an external layer, wherein the protein extract from sweet potato contains trypsin inhibitor and glycoprotein. The micro-particle comprising a protein extract from sweet potato can effectively extend satiety, control blood glucose and lipid levels and increase metabolism effectively. | 2014-12-04 |
20140356421 | Antibody-Conjugated Double-Emulsion Nanocapsule and Preparation Methods Thereof - An antibody-conjugated double-emulsion nanocapsule is provided. A linking group is introduced on the surface of a double-emulsion nanocapsule, which is composed of an oily shell enclosing an aqueous core, to link the double-emulsion nanocapsule with an antibody. | 2014-12-04 |
20140356422 | STABLE PHARMACEUTICAL FORMULATION FOR ORAL ADMINISTRATION COMPRISING LEVOCETIRIZINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND MONTELUKAST OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF - The present invention relates to a pharmaceutical formulation for oral administration for preventing or treating allergic rhinitis or asthma, which comprises: (a) a first particle part comprising levocetirizine or a pharmaceutically acceptable salt thereof and an organic acid; and (b) a second particle part comprising montelukast or a pharmaceutically acceptable salt thereof. The pharmaceutical formulation according to the present invention comprises an organic acid as a stabilizing agent, which can effectively inhibit the production of levocetirizine and montelukast related substances, and thus, show good stability. | 2014-12-04 |
20140356423 | FORMULATIONS OF LYCOPENE IN COMBINATION WITH BISPHOSPHONATES BONE RESORPTION INHIBITORS - The present invention provides a pharmaceutical formulation suitable for filling softgel capsules comprising: (a) from about 1% to about 90% by weight of a bisphosphonic acid or a pharmaceutically acceptable salt; (b) from 1% to about 99% by weight of lycopene and (c) from about 40% to about 80% by weight of a liquid carrier comprising 50% to 80% by weight polyethylene glycol; 5% to 15% by weight of glycerin; and 5% to 20% by weight water. The invention also describes a method for preparing alendronate or its pharmaceutical acceptable salts in encapsulated therapeutic dosage form in combination with lycopene. | 2014-12-04 |
20140356424 | COMPOSITION FOR TREATMENT OR REDUCTION OF SYMPTOMS RELATED TO PREMENSTRUAL SYNDROME (PMS), PREMENSTRUAL DISPHORIC DISORDER (PMDD), PREMENOPAUSE, MENOPAUSE OR FEMALE HORMONAL DISORDERS, IN A PHARMACEUTICAL COMPOSITION CONTAINING SAID FORM, AND PROCESS FOR PRODUCING SAID PHARMACEUTICAL FORM AND USE OF SAID COMPOSITION - The present invention relates to the field of food and medicines for the treatment or alleviation of premenstrual syndrome (PMS), premenstrual dysphoric disorder (PMDD), premenopause, menopause and female hormonal disorders. A first embodiment relates to a composition containing vitamins, minerals and oils. Additionally, the invention comprises a pharmaceutical form, more specifically in the form of soft capsules (also known as gelatin) containing the composition of the invention. In particular, the compositions of the invention contain vitamins and minerals in sources compatible with the association of vegetable oils, preferably borage oil, evening primrose oil, or a mixture of two oils, wherein the soft capsule contains a liquid and oily core. | 2014-12-04 |